Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > cretostimogene results DESTROYING US

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Dec 13, 2023 12:45pm

187 Views

Post# 35782442

RE:cretostimogene results DESTROYING US

Dumb and dumber which one ? This trial you posted is combination with Keytruda! Obviously leads to better results, but alone CG0007 is similar to us however, they have the same patient restrictions as Adstiladrin, so no immunocompromised patients can get this treatment. Also have many many more treatments. Combining Ruvidar with Keytruda should also lead to a significant improvement of CR rate. Have to compare apples to apples.

Dumbeldorfwhite wrote:
https://www.onclive.com/view/phase-2-data-show-clinical-activity-with-cg0070-plus-pembrolizumab-in-nmibc

68% at 12 months, pretty much matches our initial response

sadly it seems TLTs window has closed.